Search

Your search keyword '"Galella, Michael A."' showing total 114 results

Search Constraints

Start Over You searched for: Author "Galella, Michael A." Remove constraint Author: "Galella, Michael A."
114 results on '"Galella, Michael A."'

Search Results

1. Optimization of physicochemical properties of pyrrolidine GPR40 AgoPAMs results in a differentiated profile with improved pharmacokinetics and reduced off-target activities

2. Structure–activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4′ and C6 variations

4. Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists

6. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

8. Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists

10. Discovery of a Hydroxypyridinone APJ Receptor Agonist as a Clinical Candidate

11. Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK

14. Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity

15. Biphenyl Acid Derivatives as APJ Receptor Agonists

16. One-Step Diastereoselective Pyrrolidine Synthesis Using a Sulfinamide Annulating Reagent

17. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)

18. Scalable Asymmetric Synthesis of the All CisTriamino Cyclohexane Core of BMS-813160

19. Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists

20. Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis

21. Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672

22. [2.2.1]-Bicyclic sultams as potent androgen receptor antagonists

23. Sulfonylated Benzothiazoles as Inhibitors of Endothelial Lipase

24. Evolution of a Scale-Up Synthesis to a Potent GluN2B Inhibitor and Its Prodrug

30. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers

31. Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)

32. Improving the Pharmacokinetic and CYP Inhibition Profiles of Azaxanthene-Based Glucocorticoid Receptor Modulators—Identification of (S)-5-(2-(9-Fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamido)-N-(tetrahydro-2H-pyran-4-yl)-1,3,4-thiadiazole-2-carboxamide (BMS-341)

33. Novel tricyclic inhibitors of IKK2: Discovery and SAR leading to the identification of 2-methoxy- N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5- d]pyrrolo[2,3- b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066)

35. Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).

36. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists

38. Diphenylpyridylethanamine (DPPE) Derivatives as Cholesteryl Ester Transfer Protein (CETP) Inhibitors

41. Discovery of Potent and Muscle Selective Androgen Receptor Modulators through Scaffold Modifications

44. Diphenylpyridylethanamine(DPPE) Derivatives as Cholesteryl Ester Transfer Protein (CETP) Inhibitors.

48. Biphenyl AcidDerivatives as APJ Receptor Agonists

49. Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).

50. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.

Catalog

Books, media, physical & digital resources